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Biochemical and histopathological studies provide evidence of acute mitochondrial 
insult in Reye’s syndrome. These studies suggest that the metabolic abnormalities 
seen in Reye’s syndrome could be due to mitochondrial dysfunction (1). In the 
liver of Reye’s syndrome patients, the activities of all mitochondrial enzymes 
assayed to date have been decreased, whereas most of the cytoplasmic enzyme 
activities are normal. The decrease in mitochondrial enzymes could be due to 
decreased synthesis, increased degradation, inhibition, inactivation, or loss from 
liver cells into serum and other biological fluids. Our previous studies (2) and 
those of Holt et al. (3) showed that the activities of ornithine carbamyl transferase 
(an enzyme found mainly in the liver mitochondria), were elevated in the serum 
of many Reye’s syndrome patients, and maximum elevation was seen in Stage 
I patients. Recent studies by Holt et al. (3) and from our laboratory (4) showed 
that the activities of glutamate dehydrogenase (a mitochondrial enzyme) were 
also elevated in the serum of Reye’s syndrome patients. These results suggest 
that the activities of other mitochondrial enzymes that are known to decrease 
in the liver of Reye’s syndrome patients may appear in the blood. To test this 
hypothesis we determined the activities of isocitrate dehydrogenase (EC 1.1.1.42) 
in the plasma of 12 Reye’s syndrome patients. 
METHODS 
Twelve Reye’s syndrome patients admitted to the Children’s Hospital of Michigan 
during 1982-1984 were included in this study. Blood specimens were collected 
at the time of admission in heparinized tubes and immediately centrifuged at 4°C 
(SOOOg) for 15 min. Plasma was separated and stored at -70°C. 
Selection of cases was based solely on the availability of stored sera of children 
who had been diagnosed as having definite or probable Reye’s syndrome according 
to previously described criteria, and for whom pretreatment SGOT, and S-NH, 
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TABLE 1 
Serum Isocitrate Dehydrogenase Activity and Clinical Parameters in Reye’s Syndrome Patients 
Age 
(YeW Sex Stage Outcome 
SNH, SGOT SOCT SIDH 







































































values were reported for the same day, usually the day of admission, on which 
the stored samples were collected. 
SOCT activities were measured by the method of Cerriotti (5). Standard assays 
of serum GOT and ammonia were done in the clinical laboratories of the Children’s 
Hospital of Michigan for diagnostic purposes and were taken from the patient 
records. Stages were those assigned at the time of admission by the attending 
physicians and are based on the staging criteria described by Lovejoy et al. (6). 
Isocitrate dehydrogenase activity in plasma was determined at 2s”C as described 
by Bowers (7). 
RESULTS 
The activity of isocitrate dehydrogenase was elevated in most of the patients 
(21.2 4 15.5 IU/liter, mean 2 SEM, range 2-51 IU/liter). Normal range for 
isocitrate dehydrogenase activity is OS-6 IU/liter (see Table 1). 
There was no direct correlation between elevated serum isocitrate dehydrogenase 
activity and other clinical parameters such as serum ammonia, OCT, GOT, or 
the stages of the disorder. 
DISCUSSION 
Although isocitrate dehydrogense is widely distributed in body tissues (8), the 
enzyme is primarily of liver origin and marked elevations in serum isocitrate 
dehydrogenase are seen only in diseases involving hepatocellular damage. Our 
findings show that, similar to ornithine carbamyl transferase and glutamate de- 
hydrogenase, isocitrate dehydrogenase activities were also increased in the serum 
of Reye’s syndrome patients. These results support our hypothesis that the 
activities of other mitochondrial enzymes known to be decreased in the liver of 
Reye’s syndrome patients may be increased in blood. Additional measurements 
of OCT, GDH, IDH, and other mitochondrial enzymes in the sera of RS patients 
are necessary to confirm the hypothesis. Whether the activities of cytoplasmic 
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enzymes are increased in the serum of Reye’s syndrome patients also remains 
to be seen. 
Because Reye’s syndrome is a rare disorder, only a small number of samples 
was available for this study. Additional serial measurements of various metabolic 
parameters and other mitochondrial enzymes may help to clarify the relationship, 
if any, of the elevation of mitochondrial enzymes in serum to the pathogenesis 
of Reye’s syndrome. 
SUMMARY 
Serum levels of isocitrate dehydrogenase was determined in 12 Reye’s syndrome 
patients and the enzyme levels were compared with serum ornithine carbamyl 
phosphate, glutamic oxaloacetic transaminase (aspartate aminotransferase), am- 
monia, and the stages of the disorder. Isocitrate dehydrogenase was elevated in 
8 of the 12 patients and there was no direct correlation between elevated serum 
isocitrate dehydrogenase level and other clinical parameters. 
ACKNOWLEDGMENT 
We thank Dr. Janet Gilsdorf for her comments on the manuscript. 
REFERENCES 
1. DeVivo, D. C., Neurology 28, 105 (1978). 
2. Deshmukh, D. R., Rittenhouse, J. W., Mason, M., and Baublis, J. V., Enzyme 27, 45 (1982). 
3. Holt, J. T., Arvan, D. A., and Mayer, T., Lancer 2, 4 (1983). 
4. Deshmukh, D. R., Thomas, P. E., McArthur, B., and Samaik, A. P., Enzyme 33, 171 (1985). 
5. Ceniotti, G., “Clinical Biochemistry” (R. Curtins, Ed.), Vol. 2, p. 1151, de Gruyther, Berlin, 
1978. 
6. Lovejoy, F. J., Jr., Smith, A. L., and Bresnan, M. J., Amer. J. Dis. Child. 128, 36 (1974). 
7. Bowers, G. N., Jr., Clin. Chem. 5, 509 (1959). 
8. Hoffman, W. J., “The Biochemistry of Clinical Medicine,” 4th ed., Vol. 61. Yearbook, Chicago, 
1970. 
